Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Impact of home confinement during COVID-19 pandemic on Parkinson’s disease

ARTICLE INFO

Keywords
Parkinson’s disease
COVID-19
Pandemic
Home confinement
Dopamine

Home confinement (HC) during coronavirus disease 2019 (COVID-19) pandemic has affected follow-up visits and medication availability of patients with Parkinson’s disease (PWP), raising concern over their clinical stability [1]. However, a systematic assessment is lacking so far. We planned this pan-India multi-centric study to evaluate clinical stability of PWP during HC and factors associated with worsening, if any.

This cross-sectional study was conducted from May 25 to July 20, 2020. We recruited PWP aged 18 or above, following at nine Movement Disorder Centres across India, after obtaining approval from respective ethics committees. After documenting digital informed consent, an online questionnaire (Annexure 1), designed and validated by the authors, was shared with the participants using Survey Monkey Audience. Pregnant females; those with significant cognitive decline and caregivers were unavailable to respond on their behalf; patients working in essential services viz., medical, paramedical staff and policemen; and those with COVID-19 infection or quarantined for the same were excluded. The analysis was done using Statistical Package for Social Sciences (SPSS) version 21.0. Descriptive statistics were calculated. Association between categorical variables was assessed using the Chi-square test. McNemar test was used to find a change in proportion for the paired data. Bonferroni correction for multiple variables was done, wherever needed.

Of the total 851 received responses, 19 were incomplete. Analysis was done on 832 responses. The majority of respondents (83.7%) were aged 50 years or older, with nearly one-third (32.5%) in 60–69 years age-group. More than two-fifth respondents (42.9%) were from northern India, 24.7% from southern, 18.5% from eastern, and remaining from Western India. The baseline characteristics of the study population are shown in Supplemental Table 1.

While worsening in slowness, stiffness, tremor, gait, freezing of gait, and speech was reported by one-fifth PWP, a similar proportion reported worsening of non-motor symptoms viz., easy fatigability, pain, anxiety, depression, constipation, and forgetfulness (Table 1). Sleep disturbances were reported by 35.4% respondents, with 23.9% reporting worsening or new-onset sleep disturbances within the past 3 months (Supplemental Table 1). Overall 38.5% patients reported worsening of PD symptoms.

Association of worsening in motor and non-motor symptoms was analyzed with independent factors including available support at home during HC, duration of HC, PD duration and difficulty in seeking formal neurology consultations (FNCs) and/or medicines for PD (PD-meds) (Supplemental Table 2). HC duration >60 days was significantly associated with worsening in tremor (P = 0.003), speech (P = 0.002), and urinary problems (P < 0.001). Worsening in gait and postural dizziness were significantly associated with lack of available support at home during HC (P < 0.001) and PD duration > 7 years (P = 0.004), respectively. Sleep disturbances were common in those lacking adequate support at home during HC (P = 0.011), HC duration > 60 days (P = 0.004) and PD duration > 7 years (P = 0.003) (Supplemental Table 2).

Interestingly, one-third patients (33.9%) who adopted new exercises/hobbies during HC experienced significantly reduced worsening in slowness (P = 0.001). Although difficulty in seeking FNCs and/or PD-meds was not an independent predictor of symptomatic worsening, it was reported by 42.3% patients, with lack of transport facility (31%) being the most common reason. Medication unavailability was reported by 7.5% patients. While there was no significant change in duration of daily physical exercise (P = 0.203), daily screen time significantly increased during HC (P < 0.001) (Supplemental Table 1). During HC, 54.2% patients reported dissatisfaction with their quality of life, with worsening of PD symptoms (38.5%) and fear of contracting COVID-19 (19.5%) being the common reasons.

Our multicenter study shows worsening/appearance of new motor and/or non-motor symptoms in 38.5% PWP. Only 5% PWP reported similar worsening in a recent study conducted in the initial weeks of HC [1]. Stress resulting from COVID-19 pandemic and prolonged HC may result in global motor worsening in PD [2]. Additionally, staying in a confined space might worsen gait and increase freezing [3]. Deficiency in dopamine-dependent adaptation, essential for coping with stress during COVID-19 pandemic, may worsen depressive and anxiety symptoms [2]. Depressive and anxiety symptoms along with increased screen time might have worsened sleep in our patients [4].

Medication unavailability (7.5%) was not a major concern in our patients, probably related to largely undisrupted pharmaceutical supply during the pandemic. Only 2% cases reported medication unavailability in the initial weeks of HC [1]. A major limitation of our study was the inability to physically examine patients and confirm their responses, with likely under- or overestimation of worsening. Majority of physical examination of PD patients, except rigidity and postural reflexes, can be shared on video and use of telemedicine may benefit them during the
Table 1
Perception about change in motor and non-motor symptoms in Parkinson’s disease patients during home confinement as compared to pre-home confinement period.

| Sl. No. | Clinical characteristics (n = 852) | Never had this symptom (n; %) | No worsening (n; %) | Worsening (n; %) |
|---------|----------------------------------|-------------------------------|-------------------|-----------------|
| A. Motor symptoms | | | | |
| 1 | Tremor | 99 (11.9) | 560 (67.3) | 173 (20.8) |
| 2 | Stiffness | 118 (14.2) | 511 (61.4) | 203 (24.4) |
| 3 | Slowness | 63 (7.6) | 510 (61.3) | 259 (31.1) |
| 4 | Reduced clarity of voice | 337 (40.5) | 344 (41.4) | 151 (18.2) |
| 5 | Difficulty in swallowing | 619 (74.4) | 151 (18.2) | 62 (7.5) |
| 6 | Drooling of saliva | 568 (68.3) | 194 (23.3) | 70 (8.4) |
| 7 | Difficulty in walking | 163 (19.6) | 424 (50.9) | 245 (29.4) |
| 8 | Freezing of gait | 408 (49.04) | 260 (31.3) | 164 (19.7) |
| 9 | Falls | 500 (60.1) | 210 (25.4) | 121 (14.5) |
| 10 | Use of walking aid | 551 (66.2) | 189 (22.7) | 92 (11.1) |
| 11 | Dyskinesia | 578 (69.5) | 185 (22.2) | 69 (8.3) |
| B. Non-motor symptoms | | | | |
| 1 | Forgetfulness | 412 (49.5) | 271 (32.6) | 149 (17.9) |
| 2 | Aggressive or impulsive behaviour | 559 (67.2) | 177 (21.3) | 96 (11.5) |
| 3 | Depressive symptoms | 408 (49.03) | 256 (30.8) | 168 (20.2) |
| 4 | Anxiety symptoms | 407 (48.9) | 246 (29.6) | 179 (21.5) |
| 5 | Visual hallucinations | 676 (81.3) | 196 (23.7) | 50 (6.01) |
| 6 | Auditory hallucinations | 705 (84.7) | 92 (11.05) | 35 (4.2) |
| 7 | Obsessive thoughts | 618 (74.3) | 153 (18.6) | 79 (9.5) |
| 8 | Pain | 372 (44.7) | 279 (33.5) | 181 (21.8) |
| 9 | Urinary problems | 439 (52.8) | 282 (33.9) | 111 (13.3) |
| 10 | Constipation | 262 (31.5) | 407 (48.9) | 163 (19.6) |
| 11 | Easy fatigue | 252 (30.3) | 371 (44.6) | 209 (25.1) |
| 12 | Postural dizziness | 496 (59.6) | 228 (27.4) | 108 (12.9) |
| 13 | Sleep disturbances | 537 (64.5) | 96 (11.5) | 199 (23.9) |

COVID-19 pandemic [5].

Disclosures (related to this manuscript)

Drs. Kumar N, Gupta R, Kumar H, Mehta S, Rajan R, Kandadai RM, Desai S, Wadap, Basu P, Mishal B, Prashanth LK, Srivastava AK and Goyal V report no disclosures relevant to the manuscript. Kumar D, Mondal B, Sanchita, Rawat A, Meka SS, report no disclosures relevant to the manuscript.

Funding

We report no funding for this study.

Authorship

Dr. Niraj Kumar: Conception and design of the study, Analysis and interpretation of data, Preparing the first draft of the manuscript, Final approval of the version.

Dr. Ravi Gupta: Conception and design of the study, Analysis and interpretation of data, Review and Critique, Final approval of the version.

Dr. Hrishikesh Kumar: Review and Critique, Final approval of the version.

Dr. Sahil Mehta: Review and Critique, Final approval of the version.

Dr. Roopa Rajan: Review and Critique, Final approval of the version.

Dr. Soaham Desai: Acquisition of data, Review and Critique, Final approval of the version.

Dr. Pettarusp Wadia: Review and Critique, Final approval of the version.

Dr. Purba Basu: Acquisition of data, Final approval of the version.

Banashree Mondal: Acquisition of data, Final approval of the version.

Sanchita: Acquisition of data, Final approval of the version.

Ankita Rawat: Acquisition of data, Final approval of the version.

Bhushan Mishal: Acquisition of data, Final approval of the version.

Dr. Prashanth LK: Review and Critique, Final approval of the version.

Dr. Achal Kumar Srivastava: Review and Critique, Final approval of the version.

Dr. Vinay Goyal: Review and Critique, Final approval of the version.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.parkreldis.2020.09.003.

References

[1] S. Prasad, V.V. Holla, K. Neeraja, et al., Parkinson’s disease and COVID-19: perceptions and implications in patients and caregivers, Mov. Disord. 35 (6) (2020) 912–914.

[2] R.C. Helmich, B.R. Bloem, The impact of the COVID-19 pandemic on Parkinson’s disease: hidden sorrows and emerging opportunities, J. Parkinsons Dis. 10 (2) (2020) 351–354.

[3] S. Rahman, H.J. Griffin, N.P. Quinn, M. Jahanshahi, The factors that induce or overcome freezing of gait in Parkinson’s disease, Behav. Neurol. 19 (3) (2008) 127–136.

[4] R. Gupta, S. Grover, A. Basu, et al., Changes in sleep pattern and sleep quality during COVID-19 lockdown, Indian J. Psychiatr. 62 (4) (2020 Jul 1) 370.

[5] S.M. Papa, P. Brundin, V.S.C. Fung, et al., Impact of the COVID-19 pandemic on Parkinson’s disease and movement disorders, Mov. Disord. Clin. Pract. 7 (4) (2020) 357–360.

Niraj Kumar

Department of Neurology, All India Institute of Medical Sciences, Rishikesh, India

Ravi Gupta

Department of Psychiatry, All India Institute of Medical Sciences, Rishikesh, India

Hrishikesh Kumar

Department of Neurology, Institute of Neurosciences, Kolkata, India

Sahil Mehta

Department of Neurology, Post Graduate Institute of Medical Education and Research, Chandigarh, India

Roopa Rajan

Department of Neurology, All India Institute of Medical Sciences, New Delhi, India

Deva Kumar

Center for Parkinson’s Disease and Movement Disorders, Vikram Hospital, Bengaluru, India

Rukmini Mridula Kandadai

Department of Neurology, Nizams Institute of Medical Sciences, Hyderabad, India

Soaham Desai

Department of Neurology, Shree Krishna Hospital, Karamsad, Anand, India

Pettarusp Wadia

Department of Neurology, Jaslok Hospital, Mumbai, India

Purba Basu, Banashree Mondal

Department of Neurology, Institute of Neurosciences, Kolkata, India

Sanchita

Department of Neurology, Post Graduate Institute of Medical Education and Research, Chandigarh, India
Ankita Rawat  
Department of Neurology, All India Institute of Medical Sciences, Rishikesh, India

Sai Srilakshmi Meka  
Department of Neurology, Nizams Institute of Medical Sciences, Hyderabad, India

Bhushan Mishal  
Department of Neurology, Jaslok Hospital, Mumbai, India

L.K. Prashanth  
Center for Parkinson’s Disease and Movement Disorders, Vikram Hospital, Bengaluru, India

Achal Kumar Srivastava  
Department of Neurology, All India Institute of Medical Sciences, New Delhi, India

Vinay Goyal  
Department of Neurology, Medanta Hospital, Gurugram, India

* Corresponding author. Dept. of Neurology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India  
E-mail addresses: drnirajkumarsingh@gmail.com, niraj.neuro@aiimsrishikesh.edu.in (N. Kumar).